US20020015715A1 - Gel formulations for topical drug delivery - Google Patents

Gel formulations for topical drug delivery Download PDF

Info

Publication number
US20020015715A1
US20020015715A1 US09/325,369 US32536999A US2002015715A1 US 20020015715 A1 US20020015715 A1 US 20020015715A1 US 32536999 A US32536999 A US 32536999A US 2002015715 A1 US2002015715 A1 US 2002015715A1
Authority
US
United States
Prior art keywords
percent
formulation
imidazo
ethoxymethyl
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/325,369
Other versions
US6365166B2 (en
Inventor
Joseph M. Beaurline
Patrick J. Roddy
Mark A. Tomai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicis Pharmaceutical Corp
Original Assignee
Joseph M. Beaurline
Patrick J. Roddy
Mark A. Tomai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joseph M. Beaurline, Patrick J. Roddy, Mark A. Tomai filed Critical Joseph M. Beaurline
Priority to US09/325,369 priority Critical patent/US6365166B2/en
Publication of US20020015715A1 publication Critical patent/US20020015715A1/en
Application granted granted Critical
Publication of US6365166B2 publication Critical patent/US6365166B2/en
Assigned to GRACEWAY PHARMACEUTICALS, LLC reassignment GRACEWAY PHARMACEUTICALS, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: 3M INNOVATIVE PROPERTIES COMPANY
Assigned to BANK OF AMERICA, N.A., AS FIRST LIEN COLLATERAL AGENT reassignment BANK OF AMERICA, N.A., AS FIRST LIEN COLLATERAL AGENT FIRST LIEN GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS AND TRADEMARKS Assignors: CHESTER VALLEY PHARMACEUTICALS, LLC, GRACEWAY PHARMACEUTICALS, LLC
Assigned to BANK OF AMERICA, N.A., AS SECOND LIEN COLLATERAL AGENT reassignment BANK OF AMERICA, N.A., AS SECOND LIEN COLLATERAL AGENT SECOND LIEN GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS AND TRADEMARKS Assignors: CHESTER VALLEY PHARMACEUTICALS, LLC, GRACEWAY PHARMACEUTICALS, LLC
Assigned to CHESTER VALLEY PHARMACEUTICALS, LLC, GRACEWAY PHARMACEUTICALS, LLC reassignment CHESTER VALLEY PHARMACEUTICALS, LLC RELEASE OF SECOND LIEN SECURITY AGREEMENT IN PATENTS Assignors: BANK OF AMERICA, N.A.
Assigned to BANK OF AMERICA, N.A., AS FIRST LIEN COLLATERAL AGENT reassignment BANK OF AMERICA, N.A., AS FIRST LIEN COLLATERAL AGENT FIRST LIEN GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS AND TRADEMARKS Assignors: CHESTER VALLEY PHARMACEUTICALS, LLC, GRACEWAY PHARMACEUTICALS, LLC
Assigned to GRACEWAY PHARMACEUTICALS, LLC, CHESTER VALLEY PHARMACEUTICALS, LLC reassignment GRACEWAY PHARMACEUTICALS, LLC RELEASE OF FIRST LIEN SECURITY AGREEMENT IN PATENTS Assignors: BANK OF AMERICA, N.A.
Assigned to DEUTSCHE BANK TRUST COMPANY AMERICAS, AS SECOND LIEN COLLATERAL AGENT reassignment DEUTSCHE BANK TRUST COMPANY AMERICAS, AS SECOND LIEN COLLATERAL AGENT SECOND LIEN GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS AND TRADEMARKS Assignors: CHESTER VALLEY PHARMACEUTICALS, LLC, GRACEWAY PHARMACEUTICALS, LLC
Assigned to MEDICIS PHARMACEUTICAL CORPORATION reassignment MEDICIS PHARMACEUTICAL CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GRACEWAY PHARMACEUTICALS, LLC
Assigned to GOLDMAN SACHS LENDING PARTNERS LLC reassignment GOLDMAN SACHS LENDING PARTNERS LLC SECURITY AGREEMENT Assignors: MEDICIS PHARMACEUTICAL CORPORATION
Assigned to BARCLAYS BANK PLC, AS SUCCESSOR AGENT reassignment BARCLAYS BANK PLC, AS SUCCESSOR AGENT NOTICE OF SUCCESSION OF AGENCY Assignors: GOLDMAN SACHS LENDING PARTNERS, LLC
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Definitions

  • This invention relates to improved pharmaceutical gel formulations for the topical delivery of drugs.
  • this invention relates to pharmaceutical topical gel formulations containing 4-amino-2-ethoxymethyl- ⁇ , ⁇ -dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol.
  • compositions for topical delivery of drugs are well known. However, many such formulations are not suitable for certain applications due to problems with, for example, insolubility and/or degradation of the drug in the formulation, physical instability of the formulation (separation of components, thickening, precipitation/agglomerization of active ingredient, and the like), and due to irritation of the skin or mucosa to which the formulation is applied. Also, depending on the purpose of the formulation, it may be desirable if the formulation avoids systemic delivery of the active ingredient, particularly where side effects may result from such systemic delivery.
  • U.S. Pat. No. 5,238,944 discloses a topical formulation of 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine which is effective for the treatment of genital warts and other diseases.
  • this formulation is a cream, subject to potential separation problems, and includes isostearic acid which makes it painful if applied to open lesions such as occur in the case of herpes simplex virus infection.
  • the compound 4-amino-2-ethoxymethyl- ⁇ , ⁇ -dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol disclosed in U.S. Pat. No. 5,389,640 is from the same chemical class of compounds as 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine, although having some significantly different chemical, physical, and biological properties.
  • the compound has been shown to induce interferon and tumor necrosis factor in mice and rats following oral administration.
  • the compound has also been shown to induce interferon-a, tumor necrosis factor, interleukin-1 ⁇ , interleukin-1 ⁇ , interleukin-6 and interleukin-8 in cultures of human peripheral blood mononuclear cells.
  • the compound has also shown antiviral activity against herpes simplex virus-challenged guinea pigs when administered subcutaneously, dermally or intravaginally 24 hours before infection.
  • a related object is to provide a gel formulation that is suitable for application to skin and/or mucosal lesions.
  • Another object is to provide a gel formulation in which 4-amino-2-ethoxymethyl- ⁇ , ⁇ -dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol is soluble and does not substantially degrade during storage.
  • Yet another object is to provide a topical gel formulation for the topical delivery of 4-amino-2-ethoxymethyl- ⁇ , ⁇ -dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol which does not deliver undue amounts of the active compound systemically.
  • compositions including a drug, colloidal silicon dioxide, triacetin and, preferably, propylene glycol.
  • the drug is preferably 4-amino-2-ethoxymethyl- ⁇ , ⁇ -dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, which has been found to be sufficiently soluble and chemically stable in gel formulations of the present invention.
  • gel formulations of the present invention unlike certain other gel formulations, provide excellent topical delivery of the drug while substantially avoiding unwanted systemic delivery (thereby avoiding side effects).
  • the gel formulations of the invention preferably include propylene glycol.
  • propylene glycol thickens the gel formulations and that the integrity of the resulting gel is maintained at body temperature. It should be noted, however, that gel formulations without propylene glycol, but including 4-amino-2-ethoxymethyl- ⁇ , ⁇ -dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, colloidal silicon dioxide, and triacetin have been found to be suitable, although less preferred.
  • the present invention also provides a method of inducing cytokines, such as interferon and tumor necrosis factor, locally in the skin or mucous membranes of a mammal, comprising placing on the skin or mucous membranes of a mammal an amount of a formulation as described above effective to induce cytokines.
  • cytokines such as interferon and tumor necrosis factor
  • the formulations of the present invention are also well-suited for treatment of diseases by application of the formulation to skin and/or mucosal lesions because the gel formulations do not need to include irritating components.
  • FIG. 1 is a modified Franz diffusion cell drug release test apparatus
  • FIG. 2 is an alternative modified Franz diffusion cell drug release test apparatus.
  • the present invention provides gel formulations preferably containing 4-amino-2-ethoxymethyl- ⁇ , ⁇ -dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol (sometimes referred to herein as “the drug”).
  • the compound 4-amino-2-ethoxymethyl- ⁇ , ⁇ -dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol is a known immune response enhancer with antiviral properties. It can be synthesized using the method disclosed in U.S. Pat. No. 5,389,640, the disclosure of which is incorporated herein by reference.
  • the compound can be used to treat viral infections such as Type I or Type II Herpes simplex viral infections and genital warts.
  • the fact that the compound induces a variety of cytokines including interferon suggests that it and topical formulations containing it may be useful in the treatment of other diseases where interferon has been shown to be effective.
  • the 4-amino-2-ethoxymethyl- ⁇ , ⁇ -dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol will preferably be present in a formulation of the invention in a therapeutically effective amount i.e., an amount effective to treat the targeted disease state or to prevent the recurrence of such a disease.
  • a therapeutically effective amount i.e., an amount effective to treat the targeted disease state or to prevent the recurrence of such a disease.
  • 4-amino-2-ethoxymethyl- ⁇ , ⁇ -dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol will preferably be present in a formulation of the invention in an amount of 0.001 to about 0.6 percent by weight, more preferably about 0.01 to about 0.5 percent by weight based on the total weight of the formulation.
  • Formulations of the invention contain colloidal silicon dioxide as a gelling agent.
  • Colloidal silicon dioxide is commercially available under several trade names: AEROSIL from Degussa (Deutsche Gold- und Silber-Schneideweg vormals Roessler, Frankfurt, Germany), CAB-O-SIL from Cabot Corporation (Tuscola, Ill., USA), and Wacker HDK from Wacker-Chemie GmbH (Munich, Germany).
  • AEROSIL Several grades of colloidal silicon dioxide having different surface areas are commercially available. A preferred grade has a specific surface area of about 200 m 2 /g and is available under the trade designation AEROSIL 200.
  • Colloidal silicon dioxide will generally be present in a formulation of the invention in an amount of about 7 to about 12 percent, preferably about 8 to about 11 percent by weight based on the total weight of the formulation.
  • Formulations of the invention preferably contain propylene glycol (1,2-propanediol).
  • propylene glycol has been found, surprisingly, to thicken the gel formulations and to provide a gel that maintains its integrity at body temperature. It is believed that the propylene glycol may act as a solvent for the colloidal silicon dioxide and as a solubilizer for the drug.
  • propylene glycol will preferably be present in a formulation of the invention in an amount of about 1 to about 30 percent, and more preferably about 5 to about 25 percent by weight based on the total weight of the formulation.
  • Formulations of the invention also contain triacetin (1,2,3-propanetriol triacetate).
  • the triacetin is believed to act as a solvent for the colloidal silicon dioxide and as a solubilizer for the drug.
  • triacetin will generally be present in amount of about 88 to about 93 percent by weight based on the total weight of the formulation.
  • triacetin will generally be present in an amount of about 58 to about 92 percent, preferably about 63 to about 88 percent by weight based on the total weight of the formulation.
  • the actual percentages of the triacetin and other ingredients will depend on whether other ingredients are included in the formulation.
  • a formulation of the present invention can be prepared by combining the 4-amino-2-ethoxymethyl- ⁇ , ⁇ -dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol with the triacetin and propylene glycol, if present, and then heating with mixing to a temperature of about 50-55° C.
  • the 4-amino-2-ethoxymethyl- ⁇ , ⁇ -dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol appears to be completely dissolved, the colloidal silicon dioxide is added and mixed until wetted. The resulting mixture is sheared on a high speed propeller mixer until a homogeneous gel is formed.
  • Formulations of the invention have been found to induce interferon and tumor necrosis factor locally in the skin of mice. Local induction helps avoid the side effects associated with the systemic induction of these cytokines. As previously mentioned, these side effects include fever, malaise, headache, nausea and vomiting.
  • the ability of the formulations of the invention to induce interferon and tumor necrosis factor in the skin suggests that they will be useful for the topical treatment of diseases such as Type I and Type II Herpes simplex infections, warts including genital warts, basal cell carcinoma, cervical intraepithelial neoplasia and actinic keratosis.
  • mice For each formulation being tested, two groups of hairless SKH-1 female mice (four mice per group) are dosed. A 10 ⁇ L portion of the drug containing formulation is applied to the right flank and rubbed in for 1 minute. A 10 ⁇ L portion of placebo gel (which contains the same weight percent of silicon dioxide and propylene glycol as the test gel with the remainder being triacetin) is applied to the left flank and rubbed in for 1 minute. One hour after dosing the first group of mice is sacrificed. Two hours after dosing the second group of mice is sacrificed. The skin is washed and tissue samples (100 mg) are removed from the right flank (drug treated) and the left flank (placebo treated). Individual samples are placed in cryovials and snap frozen in liquid nitrogen.
  • TNF tumor necrosis factor
  • INF interferon
  • the method is as follows: interferon dilutions and L929 cells are incubated at 37° C. for 12 to 24 hours. The incubated cells are infected with an inoculum of encephalomyocarditis virus. The infected cells are incubated for an additional period at 37° C. before quantifying for viral cytopathic effect. The viral cytopathic effect is quantified by staining followed by spectrophotometric absorbance measurements. Results are expressed as units/mL ⁇ SEM based on the value obtained for NIH mouse interferon reference standard.
  • a modified Franz diffusion cell 10 of the type shown in FIG. 1 is used.
  • the cell is made of glass and holds approximately 11 mL of receptor fluid in the cell body.
  • the cell body opening is 1.6 cm in diameter (2.0 cm 2 area).
  • a section of synthetic membrane 11 (microporous polyethylene film, CoTranTM 9711 from 3M Company) is mounted between the upper portion 13 and lower portion 15 of the cell.
  • the membrane is held in place by means of a Teflon® O-ring 14 .
  • the upper and lower portions are held together by means of a clamp (not illustrated).
  • receptor fluid 0.1M sodium acetate buffer, pH 4.0
  • the receptor fluid is stirred by means of magnetic stir bar 17 and a magnetic stirrer (not illustrated).
  • the sampling port 19 is covered except when in use.
  • the membrane When a gel formulation is evaluated, the membrane is placed across the opening of the lower portion of the diffusion cell.
  • the O-ring is positioned on top of the membrane.
  • a 1.50 g portion of formulation is placed on top of the membrane and spread evenly over the portion of the membrane surface which lies inside the O-ring.
  • the diffusion cell is assembled and the lower portion is filled with 11 mL of warm (32 ⁇ 1° C.) receptor fluid.
  • the sampling port is covered and the cell is placed in a constant temperature (32 ⁇ 1° C.) and humidity (50% ⁇ 15% relative humidity) chamber.
  • the receptor fluid is stirred throughout the experiment.
  • the entire volume of receptor fluid is withdrawn at intervals of 30, 60, 120, 240 and 360 minutes elapsed time and immediately replaced with fresh fluid.
  • the withdrawn fluid is analyzed for 4-amino-2-ethoxymethyl- ⁇ , ⁇ -dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol using a uv spectrophotometer equipped with a flow cell (1.0 cm for gels containing 0.05% or 0.01% drug; 0.2 cm for gels containing 0.25% drug) and measuring the absorbance at 247 nm. Results are reported as the cumulative amount of drug released at 30, 60, 120, 240 and 360 minutes and are expressed in units of mg/cm 2 .
  • a modified Franz diffusion cell 20 of the type shown in FIG. 2 is used. Two types of skin are used, hairless mouse skin and human cadaver skin. As shown in FIG. 2, the skin 22 is mounted between the upper portion 23 and the lower portion 25 of the cell, which are held together by means of a clamp 28 .
  • receptor fluid 0.1M sodium acetate buffer, pH 4.0
  • the receptor fluid is stirred by means of a magnetic stir bar 27 and a magnetic stirrer (not illustrated).
  • the sampling port 29 is covered except when in use.
  • the sampling port is covered and the cell is placed in a constant temperature (32 ⁇ 1° C.) and humidity (45% ⁇ 15% relative humidity) chamber.
  • the receptor fluid is stirred throughout the experiment.
  • the entire volume of receptor fluid is withdrawn at intervals of 3, 6, 12, 24, 48 and 72 hours elapsed time and immediately replaced with fresh fluid.
  • the first 5 mL of withdrawn fluid is filtered through a 0.45 ⁇ Acrodisc CRPTFE 25 mm filter (Miltex Instument Company, Ohio) and discarded.
  • a 1 mL portion is filtered and placed in a high performance liquid chromatography vial. The vial is capped then refrigerated until analysis.
  • the sample is analyzed for 4-amino-2-ethoxymethyl- ⁇ , ⁇ -dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol using high performance liquid chromatography (Column: 15 cm ⁇ 0.46 cm Supelcosil LC-8-DB (Supelco, Inc., Bellefonte, Pa., USA), 5 ⁇ m particle size; Mobile phase: acetonitrile/75 mM ammonium phosphate aqueous buffer with 5 mM triethyl amine, pH 2.5, 19%/81% v/v; Flow rate: 2.0 L/min; Detector: uv at 245 nm). Results are reported as the cumulative amount of drug penetrating at 3, 6, 12, 24, 48 and 72 hours and are expressed in units of ⁇ g/mL.
  • the gel contained 0.25% 4-amino-2-ethoxymethyl- ⁇ , ⁇ -dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, 5.0% propylene glycol, 9.0% colloidal silicon dioxide, and 85.75% triacetin.
  • the gel contained 0.25% 4-amino-2-ethoxymethyl- ⁇ , ⁇ -dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, 20.0% propylene glycol, 9.0% colloidal silicon dioxide, and 70.75% triacetin.

Abstract

Pharmaceutical gel formulations for topical drug delivery include drug, colloidal silicon dioxide, triacetin and, preferably, propylene glycol. The gel formulations are well suited for topical delivery of the drug 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, which when applied topically induces cytokines, such as interferon and tumor necrosis factor, locally in the skin or mucous membranes of a mammal. The gel formulations are also well-suited for topical delivery of drugs for treatment of diseases involving skin and/or mucosal lesions because the gel formulations do not need to include irritating components.

Description

    BACKGROUND OF THE INVENTION
  • This invention relates to improved pharmaceutical gel formulations for the topical delivery of drugs. In another aspect, this invention relates to pharmaceutical topical gel formulations containing 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol. [0001]
  • Pharmaceutical gel and cream formulations for topical delivery of drugs are well known. However, many such formulations are not suitable for certain applications due to problems with, for example, insolubility and/or degradation of the drug in the formulation, physical instability of the formulation (separation of components, thickening, precipitation/agglomerization of active ingredient, and the like), and due to irritation of the skin or mucosa to which the formulation is applied. Also, depending on the purpose of the formulation, it may be desirable if the formulation avoids systemic delivery of the active ingredient, particularly where side effects may result from such systemic delivery. [0002]
  • U.S. Pat. No. 5,238,944 discloses a topical formulation of 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine which is effective for the treatment of genital warts and other diseases. However, although useful for its intended purpose, this formulation is a cream, subject to potential separation problems, and includes isostearic acid which makes it painful if applied to open lesions such as occur in the case of herpes simplex virus infection. [0003]
  • The compound 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol disclosed in U.S. Pat. No. 5,389,640 is from the same chemical class of compounds as 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine, although having some significantly different chemical, physical, and biological properties. The compound has been shown to induce interferon and tumor necrosis factor in mice and rats following oral administration. The compound has also been shown to induce interferon-a, tumor necrosis factor, interleukin-1α, interleukin-1β, interleukin-6 and interleukin-8 in cultures of human peripheral blood mononuclear cells. The compound has also shown antiviral activity against herpes simplex virus-challenged guinea pigs when administered subcutaneously, dermally or intravaginally 24 hours before infection. [0004]
  • However, systemic administration of 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol may also be associated with certain side effects, including fever, malaise, headache, nausea and vomiting. Non-systemic topical cytokine induction would thus have the advantage of avoiding the side effects associated with the systemic induction of these ctyokines. [0005]
  • SUMMARY OF THE INVENTION
  • Accordingly, it is one object of the present to provide a highly stable pharmaceutical gel formulation that is suitable for topical application to the skin and/or mucosa. [0006]
  • A related object is to provide a gel formulation that is suitable for application to skin and/or mucosal lesions. [0007]
  • Another object is to provide a gel formulation in which 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol is soluble and does not substantially degrade during storage. [0008]
  • Yet another object is to provide a topical gel formulation for the topical delivery of 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol which does not deliver undue amounts of the active compound systemically. [0009]
  • These objects, as well as others that will become apparent upon reference to the following description, are provided by pharmaceutical gel formulations including a drug, colloidal silicon dioxide, triacetin and, preferably, propylene glycol. The drug is preferably 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, which has been found to be sufficiently soluble and chemically stable in gel formulations of the present invention. Moreover, it has been found that gel formulations of the present invention, unlike certain other gel formulations, provide excellent topical delivery of the drug while substantially avoiding unwanted systemic delivery (thereby avoiding side effects). [0010]
  • As noted, the gel formulations of the invention preferably include propylene glycol. One reason is because it appears, surprisingly, that inclusion of propylene glycol thickens the gel formulations and that the integrity of the resulting gel is maintained at body temperature. It should be noted, however, that gel formulations without propylene glycol, but including 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, colloidal silicon dioxide, and triacetin have been found to be suitable, although less preferred. [0011]
  • The present invention also provides a method of inducing cytokines, such as interferon and tumor necrosis factor, locally in the skin or mucous membranes of a mammal, comprising placing on the skin or mucous membranes of a mammal an amount of a formulation as described above effective to induce cytokines. The formulations of the present invention are also well-suited for treatment of diseases by application of the formulation to skin and/or mucosal lesions because the gel formulations do not need to include irritating components.[0012]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The invention will be described below with reference to tests conducted using apparatus shown in the accompanying drawings, wherein: [0013]
  • FIG. 1 is a modified Franz diffusion cell drug release test apparatus; and [0014]
  • FIG. 2 is an alternative modified Franz diffusion cell drug release test apparatus.[0015]
  • DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
  • All weight percentages recited herein are based on the total weight of the formulation unless otherwise indicated. [0016]
  • The present invention provides gel formulations preferably containing 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol (sometimes referred to herein as “the drug”). [0017]
  • The compound 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol is a known immune response enhancer with antiviral properties. It can be synthesized using the method disclosed in U.S. Pat. No. 5,389,640, the disclosure of which is incorporated herein by reference. The compound can be used to treat viral infections such as Type I or Type II Herpes simplex viral infections and genital warts. Furthermore, the fact that the compound induces a variety of cytokines including interferon suggests that it and topical formulations containing it may be useful in the treatment of other diseases where interferon has been shown to be effective. The 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol will preferably be present in a formulation of the invention in a therapeutically effective amount i.e., an amount effective to treat the targeted disease state or to prevent the recurrence of such a disease. Generally 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol will preferably be present in a formulation of the invention in an amount of 0.001 to about 0.6 percent by weight, more preferably about 0.01 to about 0.5 percent by weight based on the total weight of the formulation. [0018]
  • 4-Amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol exhibits substantial solubility in formulations of the invention. Accordingly in a preferred embodiment of the invention the drug is substantially fully dissolved in the formulation. [0019]
  • Formulations of the invention contain colloidal silicon dioxide as a gelling agent. Colloidal silicon dioxide is commercially available under several trade names: AEROSIL from Degussa (Deutsche Gold- und Silber-Schneideanstalt vormals Roessler, Frankfurt, Germany), CAB-O-SIL from Cabot Corporation (Tuscola, Ill., USA), and Wacker HDK from Wacker-Chemie GmbH (Munich, Germany). Several grades of colloidal silicon dioxide having different surface areas are commercially available. A preferred grade has a specific surface area of about 200 m[0020] 2/g and is available under the trade designation AEROSIL 200. Colloidal silicon dioxide will generally be present in a formulation of the invention in an amount of about 7 to about 12 percent, preferably about 8 to about 11 percent by weight based on the total weight of the formulation.
  • Formulations of the invention preferably contain propylene glycol (1,2-propanediol). The addition of propylene glycol has been found, surprisingly, to thicken the gel formulations and to provide a gel that maintains its integrity at body temperature. It is believed that the propylene glycol may act as a solvent for the colloidal silicon dioxide and as a solubilizer for the drug. Generally propylene glycol will preferably be present in a formulation of the invention in an amount of about 1 to about 30 percent, and more preferably about 5 to about 25 percent by weight based on the total weight of the formulation. [0021]
  • Formulations of the invention also contain triacetin (1,2,3-propanetriol triacetate). The triacetin is believed to act as a solvent for the colloidal silicon dioxide and as a solubilizer for the drug. In those formulations of the invention that do not contain propylene glycol, triacetin will generally be present in amount of about 88 to about 93 percent by weight based on the total weight of the formulation. In those formulations of the invention that do contain propylene glycol, triacetin will generally be present in an amount of about 58 to about 92 percent, preferably about 63 to about 88 percent by weight based on the total weight of the formulation. However, the actual percentages of the triacetin and other ingredients will depend on whether other ingredients are included in the formulation. [0022]
  • A formulation of the present invention can be prepared by combining the 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol with the triacetin and propylene glycol, if present, and then heating with mixing to a temperature of about 50-55° C. When the 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol appears to be completely dissolved, the colloidal silicon dioxide is added and mixed until wetted. The resulting mixture is sheared on a high speed propeller mixer until a homogeneous gel is formed. [0023]
  • Formulations of the invention have been found to induce interferon and tumor necrosis factor locally in the skin of mice. Local induction helps avoid the side effects associated with the systemic induction of these cytokines. As previously mentioned, these side effects include fever, malaise, headache, nausea and vomiting. The ability of the formulations of the invention to induce interferon and tumor necrosis factor in the skin suggests that they will be useful for the topical treatment of diseases such as Type I and Type II Herpes simplex infections, warts including genital warts, basal cell carcinoma, cervical intraepithelial neoplasia and actinic keratosis. [0024]
  • The examples set forth below are intended to illustrate the invention. [0025]
  • Cytokine Induction Test Method [0026]
  • The cytokine induction data given in the examples below were obtained using the following test method. [0027]
  • For each formulation being tested, two groups of hairless SKH-1 female mice (four mice per group) are dosed. A 10 μL portion of the drug containing formulation is applied to the right flank and rubbed in for 1 minute. A 10 μL portion of placebo gel (which contains the same weight percent of silicon dioxide and propylene glycol as the test gel with the remainder being triacetin) is applied to the left flank and rubbed in for 1 minute. One hour after dosing the first group of mice is sacrificed. Two hours after dosing the second group of mice is sacrificed. The skin is washed and tissue samples (100 mg) are removed from the right flank (drug treated) and the left flank (placebo treated). Individual samples are placed in cryovials and snap frozen in liquid nitrogen. The samples are then homogenized in 1 mL of RPMI medium containing 10% fetal calf serum and centrifuged at 2000 rpm for 10 minutes. The supernatants are collected and frozen until assayed for tumor necrosis factor (TNF) and interferon (INF). TNF is assayed using a commercially available ELISA kit (Genzyme, Cambridge, Mass.) and results are expressed as pg/mL±SEM. Interferon is measured by bioassay using L929 mouse fibroblasts challenged with encephalomyocarditis virus. The details of the bioassay method have been described by G. L. Brennan and L. H. Kronenberg in “Automated Bioassay of Interferons in Micro-test Plates”, Biotechniques, June/July, 78, 1983, incorporated herein by reference. Briefly stated, the method is as follows: interferon dilutions and L929 cells are incubated at 37° C. for 12 to 24 hours. The incubated cells are infected with an inoculum of encephalomyocarditis virus. The infected cells are incubated for an additional period at 37° C. before quantifying for viral cytopathic effect. The viral cytopathic effect is quantified by staining followed by spectrophotometric absorbance measurements. Results are expressed as units/mL±SEM based on the value obtained for NIH mouse interferon reference standard. [0028]
  • Drug Release Test Method [0029]
  • The drug release data given in the examples below were obtained using the following test method. [0030]
  • A modified [0031] Franz diffusion cell 10 of the type shown in FIG. 1 is used. The cell is made of glass and holds approximately 11 mL of receptor fluid in the cell body. The cell body opening is 1.6 cm in diameter (2.0 cm2 area). A section of synthetic membrane 11 (microporous polyethylene film, CoTran™ 9711 from 3M Company) is mounted between the upper portion 13 and lower portion 15 of the cell. The membrane is held in place by means of a Teflon® O-ring 14. The upper and lower portions are held together by means of a clamp (not illustrated).
  • The portion of the cell below the mounted membrane is completely filled with receptor fluid (0.1M sodium acetate buffer, pH 4.0) such that the receptor fluid is in contact with the membrane. The receptor fluid is stirred by means of [0032] magnetic stir bar 17 and a magnetic stirrer (not illustrated). The sampling port 19 is covered except when in use.
  • When a gel formulation is evaluated, the membrane is placed across the opening of the lower portion of the diffusion cell. The O-ring is positioned on top of the membrane. A 1.50 g portion of formulation is placed on top of the membrane and spread evenly over the portion of the membrane surface which lies inside the O-ring. The diffusion cell is assembled and the lower portion is filled with 11 mL of warm (32±1° C.) receptor fluid. [0033]
  • The sampling port is covered and the cell is placed in a constant temperature (32±1° C.) and humidity (50%±15% relative humidity) chamber. The receptor fluid is stirred throughout the experiment. The entire volume of receptor fluid is withdrawn at intervals of 30, 60, 120, 240 and 360 minutes elapsed time and immediately replaced with fresh fluid. The withdrawn fluid is analyzed for 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol using a uv spectrophotometer equipped with a flow cell (1.0 cm for gels containing 0.05% or 0.01% drug; 0.2 cm for gels containing 0.25% drug) and measuring the absorbance at 247 nm. Results are reported as the cumulative amount of drug released at 30, 60, 120, 240 and 360 minutes and are expressed in units of mg/cm[0034] 2.
  • In Vitro Skin Penetration Test Method [0035]
  • The skin penetration data given in the examples below was obtained using the following test method. [0036]
  • A modified [0037] Franz diffusion cell 20 of the type shown in FIG. 2 is used. Two types of skin are used, hairless mouse skin and human cadaver skin. As shown in FIG. 2, the skin 22 is mounted between the upper portion 23 and the lower portion 25 of the cell, which are held together by means of a clamp 28.
  • The portion of the cell below the mounted membrane is completely filled with receptor fluid (0.1M sodium acetate buffer, pH 4.0) such that the receptor fluid is in contact with the skin. The receptor fluid is stirred by means of a magnetic stir bar [0038] 27 and a magnetic stirrer (not illustrated). The sampling port 29 is covered except when in use.
  • When a gel formulation is evaluated, the skin is placed across the opening of the lower portion of the diffusion cell. A 300 mg portion of formulation is spread evenly over the skin. The diffusion cell is assembled and the lower portion is filled with 10 mL of warm (32±1° C.) receptor fluid. [0039]
  • The sampling port is covered and the cell is placed in a constant temperature (32±1° C.) and humidity (45%±15% relative humidity) chamber. The receptor fluid is stirred throughout the experiment. The entire volume of receptor fluid is withdrawn at intervals of 3, 6, 12, 24, 48 and 72 hours elapsed time and immediately replaced with fresh fluid. The first 5 mL of withdrawn fluid is filtered through a 0.45[0040] μ Acrodisc CRPTFE 25 mm filter (Miltex Instument Company, Ohio) and discarded. Then a 1 mL portion is filtered and placed in a high performance liquid chromatography vial. The vial is capped then refrigerated until analysis. The sample is analyzed for 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol using high performance liquid chromatography (Column: 15 cm×0.46 cm Supelcosil LC-8-DB (Supelco, Inc., Bellefonte, Pa., USA), 5 μm particle size; Mobile phase: acetonitrile/75 mM ammonium phosphate aqueous buffer with 5 mM triethyl amine, pH 2.5, 19%/81% v/v; Flow rate: 2.0 L/min; Detector: uv at 245 nm). Results are reported as the cumulative amount of drug penetrating at 3, 6, 12, 24, 48 and 72 hours and are expressed in units of μg/mL.
  • EXAMPLE 1
  • 4-Amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol (0.75 g) was added to triacetin (272.25 g) in a 600 mL glass beaker. The resulting mixture was heated (about 55° C.) with stirring until all of the drug was dissolved. Colloidal silicon dioxide (27.0 g, AEROSIL® 200 from Degussa, Frankfurt, Germany) was added to the solution and mixed with a spatula until wetted. The mixture was sheared on a high speed propeller mixer until a homogeneous gel was formed. The gel contained 0.25% 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, 9.0% colloidal silicon dioxide, and 90.75% triacetin. [0041]
  • EXAMPLE 2
  • Propylene glycol (20.0 g), triacetin (343.0 g) and 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol (1.0 g) were placed in a 600 mL glass beaker then heated (50°±5° C.) with stirring until all of the drug was dissolved. Colloidal silicon dioxide (36.0 g) was added to the solution and mixed with a spatula until wetted. The mixture was sheared on a high speed propeller mixer until a homogeneous gel was formed. The gel contained 0.25% 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, 5.0% propylene glycol, 9.0% colloidal silicon dioxide, and 85.75% triacetin. [0042]
  • EXAMPLE 3
  • Propylene glycol (80.0 g) and 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol (1.0 g) were placed in a 600 mL glass beaker then heated (about 50° C.) with stirring until all of the drug was dissolved. Triacetin (283.0 g) was added and the resulting mixture was stirred until a solution was obtained. The heat was turned off. Colloidal silicon dioxide (36.0 g) was added to the solution and mixed with a spatula until wetted. The mixture was sheared on a high speed propeller mixer until a homogeneous gel was formed. The gel contained 0.25% 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, 20.0% propylene glycol, 9.0% colloidal silicon dioxide, and 70.75% triacetin. [0043]
  • The gel formulations of Examples 1-3 were tested for their ability to induce cytokines using the test method described above. The results shown in Table 1 below demonstrate that all three formulations produced significant interferon and tumor necrosis factor induction at the site of 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol application. Results are presented as the mean±standard error mean of 4 animals assayed individually. ND means not done. [0044]
    TABLE 1
    Cytokine Induction
    Cytokine Concentration
    Right Flank Left Flank
    Time IFN TNF IFN TNF
    Formulation (hr) (U/mL) (pg/mL) (U/mL) (pg/mL)
    1 1 346 ± 54  699 ± 187 86 ± 37 273 ± 65 
    1 2 215 ± 107 496 ± 123 106 ± 98  344 ± 95 
    2 1 277 ± 80  340 ± 97  127 ± 71  163 ± 24 
    2 2 210 ± 70  610 ± 83  106 ± 105 237 ± 42 
    3 1 <1 ± 0   304 ± 39  <1 ± 0   165 ± 20 
    3 2 577 ± 210 1138 ± 232  105 ± 98  454 ± 175
    Untreated 0 3 ± 1 120 ± 15  ND ND
  • EXAMPLE 4
  • Using the method of Example 1, a gel containing 0.05% 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, 9.0% colloidal silicon dioxide, and 90.95% triacetin was prepared. [0045]
  • EXAMPLE 5
  • Using the method of Example 2, a gel containing 0.05% 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, 5.0% propylene glycol, 9.0% colloidal silicon dioxide, and 85.95% triacetin was prepared. [0046]
  • EXAMPLE 6
  • Using the method of Example 3, a gel containing 0.05% 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, 20.0% propylene glycol, 9.0% colloidal silicon dioxide, and 70.95% triacetin was prepared. [0047]
  • The gel formulations of Examples 4-6 were tested for their ability to induce cytokines using the test method described above. The results shown in Table 2 below demonstrate that all three formulations produced significant interferon and tumor necrosis factor induction at the site of 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol application. Results are presented as the mean±standard error mean of 4 animals assayed individually. ND means not done. [0048]
    TABLE 2
    Cytokine Induction
    Cytokine Concentration
    Right Flank Left Flank
    Time IFN TNF IFN TNF
    Formulation (hr) (U/mL) (pg/mL) (U/mL) (pg/mL)
    4 1 0.9 ± 0.5  412 ± 105 <1.0 280 ± 51
    4 2 20 ± 10 345 ± 72 <1.0 153 ± 19
    5 1 0.3 ± 0.3 348 ± 35 <1.0 262 ± 26
    5 2 69 ± 58 346 ± 24 <1.0 194 ± 19
    6 1 <1 ± 0   279 ± 45 <1.0 170 ± 40
    6 2 43 ± 32 260 ± 47 <1.0 129 ± 41
    Untreated 0 <1.0 220 ± 28 ND ND
  • EXAMPLE 7
  • Using the method of Example 1, a gel containing 0.01% 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, 9.0% colloidal silicon dioxide, and 90.99% triacetin was prepared. [0049]
  • EXAMPLE 8
  • Using the method of Example 2, a gel containing 0.01% 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, 5.0% propylene glycol, 9.0% colloidal silicon dioxide, and 85.99% triacetin was prepared. [0050]
  • EXAMPLE 9
  • Using the method of Example 3, a gel containing 0.01% 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, 20.0% propylene glycol, 9.0% colloidal silicon dioxide, and 70.99% triacetin was prepared. [0051]
  • The gel formulations of Examples 7-9 were tested for their ability to induce cytokines using the test method described above. The results shown in Table 3 below demonstrate that the formulation of Example 8 produced significant tumor necrosis factor induction at the site of 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol application. Results are presented as the mean±standard error mean of 4 animals assayed individually. ND means not done. [0052]
    TABLE 3
    Cytokine Induction
    Cytokine Concentration
    Right Flank Left Flank
    Time IFN TNF IFN TNF
    Formulation (hr) (U/mL) (pg/mL) (U/mL) (pg/mL)
    7 1 <1.0 455 ± 93 <1.0 421 ± 63
    7 2 <1.0 382 ± 86 <1.0 398 ± 54
    8 1 <1.0 406 ± 25 <1.0 316 ± 31
    8 2 <1.0 296 ± 23 <1.0 375 ± 18
    9 1 <1.0 380 ± 43 <1.0 352 ± 52
    9 2 <1.0 296 ± 23 <1.0 366 ± 56
    Untreated 0 <1.0 273 ± 44 ND ND
  • EXAMPLE 10
  • Using the method of Example 3, a gel containing 0.25% 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, 20.0% propylene glycol, 8.0% colloidal silicon dioxide, and 71.75% triacetin was prepared. [0053]
  • EXAMPLE 11
  • Using the method of Example 3, a gel containing 0.25% 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, 20.0% propylene glycol, 10.0% colloidal silicon dioxide, and 69.75% triacetin was prepared. [0054]
  • The gel formulations of Examples 2, 3, 5, 6, 8, 10 and 11 were tested for their ability to release 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol using the test method described above. The results shown in Table 4 below demonstrate that all five formulations release 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol. Each value is the mean of the values from 6 diffusion cells. [0055]
    TABLE 4
    Drug Release
    Cumulative Amount Released (mg/cm2)
    Formulation 30 min 60 min 120 min 240 min 360 min
    Example 2 0.13 0.18 0.24 0.41 0.56
    Example 3 0.15 0.23 0.33 0.50 0.62
    Example 5 0.03 0.04 0.05 0.09 0.11
    Example 6 0.03 0.04 0.07 0.12 0.15
    Example 8  0.024  0.041  0.062  0.091  0.108
    Example 10 0.14 0.22 0.33 0.58 0.72
    Example 11 0.12 0.17 0.25 0.45 0.59
  • The in vitro penetration of 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol through hairless mouse skin or human cadaver skin from a gel formulation of Example 3 was determined using the test method described above. The results shown in Table 5 below demonstrate that the gel releases 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol to and through the skin. Each value shown is the average of six independent determinations with the standard deviation. [0056]
    TABLE 5
    In Vitro Skin Penetration
    Time Cumulative Amount Penetrating (μg/mL)
    (hours) Hairless Mouse Skin Human Cadaver Skin
     3 0.073 ± 0.08  0
     6 0.147 ± 0.133 0
    12 0.413 ± 0.210 0
    24 1.085 ± 0.380 0
    48 2.89 ± 1.18 0.292 ± 0.088
    72 5.455 ± 3.88  0.493 ± 0.158

Claims (23)

What is claimed is:
1. A gel formulation for the topical administration of a drug, which formulation comprises a therapeutically effective amount of drug, colloidal silicon dioxide, propylene glycol, and triacetin.
2. The gel formulation of claim 1, wherein the colloidal silicon dioxide is present in an amount of about 7 to about 12 percent by weight based on the total weight of the formulation.
3. The gel formulation of claim 1, wherein the propylene glycol is present in an amount of about 1 to about 30 percent by weight based on the total weight of the formulation.
4. The gel formulation of claim 1, wherein the propylene-glycol is present in an amount of about 5 to about 25 percent by weight based on the total weight of the formulation.
5. The gel formulation of claim 1, wherein the triacetin is present in an amount of about 58 to about 92 percent by weight based on the total weight of the formulation.
6. A gel formulation for the topical administration of 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo [4,5-c]quinoline-1-ethanol, which formulation comprises:
a therapeutically effective amount of 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol;
colloidal silicon dioxide; and
triacetin.
7. The gel formulation of claim 6, further including propylene glycol.
8. A gel formulation according to claim 6, wherein 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol is present in an amount of about 0.001 percent to about 0.6 percent by weight based on the total weight of the formulation.
9. A gel formulation according to claim 6, wherein 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol is present in an amount of about 0.01 percent to about 0.5 percent by weight based on the total weight of the formulation.
10. A gel formulation according to claim 6, wherein the 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol is dissolved in the gel formulation.
11. A gel formulation according to claim 6, wherein the colloidal silicon dioxide is present in an amount of about 7 to about 12 percent by weight based on the total weight of the formulation.
12. A gel formulation according to claim 6, wherein the colloidal silicon dioxide is present in an amount of about 8 to about 10 percent by weight based on the total weight of the formulation.
13. A gel formulation according to claim 6, wherein the triacetin is present in an amount of about 88 to about 93 percent by weight based on the total weight of the formulation.
14. A gel formulation according to claim 7, wherein the triacetin is present in an amount of about 58 to about 92 percent by weight based on the total weight of the formulation.
15. A gel formulation for the topical administration of 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo [4,5-c]quinoline-1-ethanol, which formulation comprises:
(a) a therapeutically effective amount of 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol,
(b) colloidal silicon dioxide present in an amount of about 7 percent to about 12 percent by weight based on the total weight of the formulation;
(c) propylene glycol present in an amount of about 1 percent to about 30 percent by weight based on the total weight of the formulation; and
(d) triacetin present in an amount of about 58 percent to about 92 percent by weight based on the total weight of the formulation.
16. A gel formulation according to claim 15, wherein the propylene glycol is present in an amount of about 5 percent to about 25 percent by weight based on the total weight of the formulation.
17. A gel formulation according to claim 15, wherein 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol is present in an amount of about 0.001 percent to about 0.6 percent by weight based on the total weight of the formulation.
18. A gel formulation according to claim 15 comprising from about 0.05 percent to about 0.3 percent by weight 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, from about 8 percent to about 10 percent by weight colloidal silicon dioxide, and from about 90 percent to about 92 percent by weight triacetin.
19. A gel formulation according to claim 15 comprising from about 0.05 percent to about 0.3 percent by weight 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, from about 8 percent to about 10 percent by weight colloidal silicon dioxide, from about 15 percent to about 25 percent by weight propylene glycol, and from about 65 percent to about 77 percent by weight triacetin.
20. A method of inducing cytokines locally in the skin or mucous membranes of a mammal, comprising placing on the skin or mucous membranes of a mammal an amount of a gel formulation including 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol effective to induce cytokines.
21. A method of inducing interferon locally in the skin or mucous membranes of a mammal, comprising placing on the skin or mucous membranes of a mammal an amount of a gel formulation including 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol effective to induce interferon.
22. A method of inducing tumor necrosis factor locally in the skin or mucous membranes of a mammal, comprising placing on the skin or mucous membranes of a mammal an amount of a gel formulation including 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol effective to induce tumor necrosis factor.
23. The method of claim 20, where the gel formulation is applied to lesions on the skin and/or mucosa.
US09/325,369 1996-12-03 1999-06-04 Gel formulations for topical drug delivery Expired - Lifetime US6365166B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/325,369 US6365166B2 (en) 1996-12-03 1999-06-04 Gel formulations for topical drug delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/759,992 US5939090A (en) 1996-12-03 1996-12-03 Gel formulations for topical drug delivery
US09/325,369 US6365166B2 (en) 1996-12-03 1999-06-04 Gel formulations for topical drug delivery

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/759,992 Division US5939090A (en) 1996-12-03 1996-12-03 Gel formulations for topical drug delivery

Publications (2)

Publication Number Publication Date
US20020015715A1 true US20020015715A1 (en) 2002-02-07
US6365166B2 US6365166B2 (en) 2002-04-02

Family

ID=25057713

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/759,992 Expired - Lifetime US5939090A (en) 1996-12-03 1996-12-03 Gel formulations for topical drug delivery
US09/325,369 Expired - Lifetime US6365166B2 (en) 1996-12-03 1999-06-04 Gel formulations for topical drug delivery

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/759,992 Expired - Lifetime US5939090A (en) 1996-12-03 1996-12-03 Gel formulations for topical drug delivery

Country Status (18)

Country Link
US (2) US5939090A (en)
EP (1) EP0942724B1 (en)
JP (1) JP4615633B2 (en)
KR (1) KR100503716B1 (en)
AT (1) ATE245422T1 (en)
AU (1) AU723897B2 (en)
BR (1) BR9713677B1 (en)
CA (1) CA2273094C (en)
CZ (1) CZ301713B6 (en)
DE (1) DE69723721T2 (en)
DK (1) DK0942724T3 (en)
ES (1) ES2200206T3 (en)
HU (1) HU229599B1 (en)
IL (1) IL130065A (en)
NO (1) NO325684B1 (en)
NZ (1) NZ335821A (en)
PT (1) PT942724E (en)
WO (1) WO1998024436A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090324729A1 (en) * 2008-05-02 2009-12-31 Gilead Sciences, Inc. Use of solid carrier particles to improve the processability of a pharmaceutical agent
US9891239B2 (en) 2007-02-23 2018-02-13 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
EP3166976B1 (en) 2014-07-09 2022-02-23 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (en) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
US6518280B2 (en) 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
EP1495758A3 (en) * 1999-01-08 2005-04-13 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
EP1140091B1 (en) 1999-01-08 2005-09-21 3M Innovative Properties Company Formulations comprising imiquimod or other immune response modifiers for treating cervical dysplasia
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
JP3436512B2 (en) * 1999-12-28 2003-08-11 株式会社デンソー Accelerator device
US6787342B2 (en) * 2000-02-16 2004-09-07 Merial Limited Paste formulations
US6894060B2 (en) * 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
WO2001097795A2 (en) * 2000-06-22 2001-12-27 3M Innovative Properties Company Systems and methods for treating a mucosal surface
DE10033853A1 (en) * 2000-07-12 2002-01-31 Hexal Ag Transdermal therapeutic system, containing highly dispersed silicon dioxide in matrix or adhesive layer to promote drug permeation through the skin
JP2004520088A (en) 2000-08-15 2004-07-08 サーモディックス,インコーポレイティド Drug admixture matrix
US20020055517A1 (en) * 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
JP2002145777A (en) * 2000-11-06 2002-05-22 Sumitomo Pharmaceut Co Ltd Therapeutic agent for arachidonic acid-induced dermatosis
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
WO2006091720A2 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US20020110840A1 (en) * 2000-12-08 2002-08-15 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
WO2003020889A2 (en) * 2001-08-30 2003-03-13 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
US20040014779A1 (en) * 2001-11-16 2004-01-22 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like recptor pathways
EP1450804B9 (en) * 2001-11-29 2009-04-01 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
PT1478327E (en) * 2002-02-22 2015-08-04 Meda Ab Method of reducing and treating uvb-induced immunosuppression
CN1674894A (en) * 2002-06-07 2005-09-28 3M创新有限公司 Ether substituted imidazopyridines
US7700248B2 (en) * 2002-07-08 2010-04-20 Eastman Kodak Company Organic charge transporting polymers including charge transport moieties and silane groups, and silsesquioxane compositions prepared therefrom
DK1545597T3 (en) 2002-08-15 2011-01-31 3M Innovative Properties Co Immune Stimulating Compositions and Methods for Stimulating an Immune Response
JP2006503068A (en) * 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー 1H-Imidazo dimer
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
WO2004053057A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
JP2006513212A (en) 2002-12-20 2006-04-20 スリーエム イノベイティブ プロパティズ カンパニー Aryl / hetaryl substituted imidazoquinolines
EP2572714A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
EP1592302A4 (en) * 2003-02-13 2007-04-25 3M Innovative Properties Co Methods and compositions related to irm compounds and toll-like receptor 8
WO2004075865A2 (en) * 2003-02-27 2004-09-10 3M Innovative Properties Company Selective modulation of tlr-mediated biological activity
EP1601365A4 (en) 2003-03-04 2009-11-11 3M Innovative Properties Co Prophylactic treatment of uv-induced epidermal neoplasia
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
JP2006519877A (en) * 2003-03-07 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー 1-amino 1H-imidazoquinoline
WO2004080292A2 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
ATE556711T1 (en) * 2003-03-13 2012-05-15 3M Innovative Properties Co METHOD FOR IMPROVING SKIN QUALITY
JP2006523212A (en) * 2003-03-13 2006-10-12 スリーエム イノベイティブ プロパティズ カンパニー Diagnosis method of skin lesion
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
EP1617871A4 (en) * 2003-04-10 2010-10-06 3M Innovative Properties Co Delivery of immune response modifier compounds using metal-containing particulate support materials
EP1617845A4 (en) * 2003-04-28 2006-09-20 3M Innovative Properties Co Compositions and methods for induction of opioid receptors
US20050032829A1 (en) * 2003-06-06 2005-02-10 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
WO2004110991A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
US20080039533A1 (en) * 2003-07-31 2008-02-14 3M Innovative Properties Company Bioactive Compositions Comprising Triazines
CA2534313C (en) * 2003-08-05 2013-03-19 3M Innovative Properties Company Formulations containing an immune response modifier
US8211906B1 (en) 2003-08-05 2012-07-03 Scherrer Lawrence C Method of inhibiting growth of neoplastic cells and inhibiting infection by administering an immune enhancer drug
JP2007502288A (en) * 2003-08-12 2007-02-08 スリーエム イノベイティブ プロパティズ カンパニー Oxime-substituted imidazo-containing compounds
EP2939693A1 (en) * 2003-08-14 2015-11-04 3M Innovative Properties Company Lipid-modified immune response modifiers
WO2005020912A2 (en) 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
WO2005018574A2 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
AU2004268625B2 (en) 2003-08-27 2011-03-31 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
EP1663222A4 (en) * 2003-09-02 2008-05-21 3M Innovative Properties Co Methods related to the treatment of mucosal associated conditions
JP2007504269A (en) 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Method for treating CD5 + B cell lymphoma
EP1664342A4 (en) * 2003-09-17 2007-12-26 3M Innovative Properties Co Selective modulation of tlr gene expression
ES2544477T3 (en) 2003-10-03 2015-08-31 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
KR20060120069A (en) 2003-10-03 2006-11-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Pyrazolopyridines and analogs thereof
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
WO2005041891A2 (en) * 2003-10-31 2005-05-12 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
CA2545774A1 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
EP1682544A4 (en) 2003-11-14 2009-05-06 3M Innovative Properties Co Hydroxylamine substituted imidazo ring compounds
AU2004293096A1 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
NZ547467A (en) 2003-11-25 2010-06-25 3M Innovative Properties Co Substituted imidazo ring system and methods
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
WO2005055932A2 (en) * 2003-12-02 2005-06-23 3M Innovative Properties Company Therapeutic combinations and methods including irm compounds
US6943470B2 (en) * 2003-12-02 2005-09-13 Siemens Westinghouse Power Corporation Air gap baffle assembly for gas-cooled turbine generator and method of installing
AU2004315771A1 (en) * 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
AU2004312510A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
JP2007517035A (en) 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー Arylalkenyl and arylalkynyl substituted imidazoquinolines
EP1699398A4 (en) * 2003-12-30 2007-10-17 3M Innovative Properties Co Enhancement of immune responses
EP1699788A2 (en) 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides
ES2665342T3 (en) * 2004-03-15 2018-04-25 Meda Ab Formulations and methods for immune response modifiers
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US20070166384A1 (en) * 2004-04-09 2007-07-19 Zarraga Isidro Angelo E Methods , composition and preparations for delivery of immune response modifiers
CN101426524A (en) * 2004-04-28 2009-05-06 3M创新有限公司 Compositions and methods for mucosal vaccination
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
WO2005123079A2 (en) * 2004-06-14 2005-12-29 3M Innovative Properties Company Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006028545A2 (en) * 2004-06-18 2006-03-16 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US20060045886A1 (en) * 2004-08-27 2006-03-02 Kedl Ross M HIV immunostimulatory compositions
WO2006026760A2 (en) * 2004-09-02 2006-03-09 3M Innovative Properties Company 1-amino imidazo-containing compounds and methods
PL1789042T3 (en) * 2004-09-02 2012-09-28 3M Innovative Properties Co 1-alkoxy 1h-imidazo ring systems and methods
AU2005282523A1 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1H imidazo ring systems and methods
US20080193468A1 (en) * 2004-09-08 2008-08-14 Children's Medical Center Corporation Method for Stimulating the Immune Response of Newborns
US20070243215A1 (en) * 2004-10-08 2007-10-18 Miller Richard L Adjuvant for Dna Vaccines
WO2006063072A2 (en) * 2004-12-08 2006-06-15 3M Innovative Properties Company Immunomodulatory compositions, combinations and methods
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
ES2392647T3 (en) 2004-12-30 2012-12-12 3M Innovative Properties Company Chiral tetracyclic compounds that induce interferon biosynthesis
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
WO2006071997A2 (en) 2004-12-30 2006-07-06 3M Innovative Properties Company Treatment for cutaneous metastases
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
KR20070107685A (en) * 2004-12-30 2007-11-07 다케다 야쿠힌 고교 가부시키가이샤 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate
WO2006084251A2 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
ES2475728T3 (en) 2005-02-09 2014-07-11 3M Innovative Properties Company Thiazoloquinolines and alkoxy substituted thiazolonaphthyridines
EP1877056A2 (en) 2005-02-09 2008-01-16 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazoloý4,5-c¨ring compounds and methods
JP2008532933A (en) 2005-02-11 2008-08-21 コーリー ファーマシューティカル グループ,インコーポレイテッド Substituted imidazoquinolines and substituted imidazonaphthyridines
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
EP1850849A2 (en) 2005-02-23 2007-11-07 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
JP2008531568A (en) 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ,インコーポレイテッド Imidazonaphthyridine substituted with hydroxyalkyl
AU2006223634A1 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
AU2006216798A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
JP2008533148A (en) 2005-03-14 2008-08-21 スリーエム イノベイティブ プロパティズ カンパニー Treatment method for actinic keratosis
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
US20080193474A1 (en) * 2005-04-25 2008-08-14 Griesgraber George W Immunostimulatory Compositions
US8476292B2 (en) 2005-09-09 2013-07-02 3M Innovative Properties Company Amide and carbamate derivatives of N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
US8088790B2 (en) 2005-11-04 2012-01-03 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
WO2007079203A2 (en) * 2005-12-28 2007-07-12 3M Innovative Properties Company Treatment for cutaneous t cell lymphoma
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co Immune response modifier conjugates
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
AU2007275815A1 (en) * 2006-07-18 2008-01-24 Wirra Ip Pty. Ltd. Immune response modifier formulations
US8124096B2 (en) * 2006-07-31 2012-02-28 3M Innovative Properties Company Immune response modifier compositions and methods
WO2008030511A2 (en) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
WO2011084725A1 (en) * 2009-12-21 2011-07-14 3M Innovative Properties Company 4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
DK2606047T3 (en) 2010-08-17 2017-03-27 3M Innovative Properties Co COMPOSITIONS AND FORMULATIONS WITH LIPIDIZED IMMUNE RESPONSE-MODIFIING COMPOUND AND PROCEDURES THEREOF
US9475804B2 (en) 2011-06-03 2016-10-25 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
MX355623B (en) 2011-06-03 2018-04-25 3M Innovative Properties Co Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom.
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
WO2013162828A1 (en) 2012-04-27 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Use of cpg oligonucleotides co-formulated with an antibiotic to accelarate wound healing
NZ701324A (en) 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
CN113842362A (en) 2012-11-14 2021-12-28 格雷斯公司 Compositions comprising bioactive materials and disordered inorganic oxides
EP3932401A1 (en) * 2014-09-02 2022-01-05 Epien Medical Inc. Formulation for treating chronic wounds
WO2016063265A2 (en) * 2014-10-24 2016-04-28 Palmeira De Oliveira Rita Manuela Topical formulation for treating skin or mucosal infections, preparation method and uses thereof
CA3049254A1 (en) 2017-01-10 2018-07-19 Nektar Therapeutics Multi-arm polymer conjugates of tlr agonist compounds and related immunotherapeutic treatment methods
CN111511740B (en) 2017-12-20 2023-05-16 3M创新有限公司 Amide substituted imidazo [4,5-C ] quinoline compounds with branched linking groups for use as immune response modifiers
WO2020226889A1 (en) * 2019-05-07 2020-11-12 Wellstat Therapeutics Corporation Formulations of uridine triacetate in triacetin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA831186B (en) * 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
CA1272953A (en) * 1984-10-08 1990-08-21 Yuji Makino Pharmaceutical composition for external use containing active-type vitamin d.sub.3
ES2032861T3 (en) 1986-07-14 1993-03-01 Sandoz Ag PROCEDURE FOR PREPARING A 5-HETERO- OR ARYL-SUBSTITUTED-IMIDAZO (2,1-A) ISOQUINOLINE MEDICATION.
US4788064A (en) * 1987-07-31 1988-11-29 Warner-Lambert Company Transdermal delivery system
US4814173A (en) * 1987-09-08 1989-03-21 Warner-Lambert Company Silicone elastomer transdermal matrix system
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
IL92537A (en) * 1988-12-15 1994-04-12 Riker Laboratories Inc Topical formulations and transdermal delivery systems containing- isobutyl-1H-imidazo [4,5-c] quinolin-4-amine
EP0385630B1 (en) * 1989-02-27 1996-11-27 Riker Laboratories, Inc. 1H-imidazo(4,5-c)Quinolin-4-amines as antivirals
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
EP0582581B1 (en) * 1991-03-01 1999-05-06 Minnesota Mining And Manufacturing Company 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES
DE4117249C2 (en) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomine used to treat erectile dysfunction

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9891239B2 (en) 2007-02-23 2018-02-13 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
US20090324729A1 (en) * 2008-05-02 2009-12-31 Gilead Sciences, Inc. Use of solid carrier particles to improve the processability of a pharmaceutical agent
US10039718B2 (en) 2008-05-02 2018-08-07 Gilead Sciences, Inc. Use of solid carrier particles to improve the processability of a pharmaceutical agent
EP3166976B1 (en) 2014-07-09 2022-02-23 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors

Also Published As

Publication number Publication date
HUP0000568A2 (en) 2000-10-28
HUP0000568A3 (en) 2001-01-29
DE69723721D1 (en) 2003-08-28
KR100503716B1 (en) 2005-07-26
AU5368698A (en) 1998-06-29
WO1998024436A2 (en) 1998-06-11
CZ195599A3 (en) 1999-09-15
DK0942724T3 (en) 2003-11-17
BR9713677A (en) 2000-03-28
CZ301713B6 (en) 2010-06-02
NZ335821A (en) 2001-04-27
EP0942724A2 (en) 1999-09-22
EP0942724B1 (en) 2003-07-23
DE69723721T2 (en) 2004-04-15
ATE245422T1 (en) 2003-08-15
IL130065A (en) 2004-06-20
NO992638D0 (en) 1999-06-01
NO325684B1 (en) 2008-07-07
AU723897B2 (en) 2000-09-07
CA2273094A1 (en) 1998-06-11
CA2273094C (en) 2005-08-16
PT942724E (en) 2003-12-31
IL130065A0 (en) 2000-02-29
NO992638L (en) 1999-07-16
JP4615633B2 (en) 2011-01-19
KR20000069233A (en) 2000-11-25
US5939090A (en) 1999-08-17
ES2200206T3 (en) 2004-03-01
US6365166B2 (en) 2002-04-02
JP2001501968A (en) 2001-02-13
BR9713677B1 (en) 2009-05-05
HU229599B1 (en) 2014-02-28
WO1998024436A3 (en) 1998-08-06

Similar Documents

Publication Publication Date Title
US6365166B2 (en) Gel formulations for topical drug delivery
US5314685A (en) Anhydrous formulations for administering lipophilic agents
EP0526561B1 (en) Composition for transdermal penetration of medicaments
US7244447B2 (en) Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
EP0974350B1 (en) External preparation containing tranilast and process for producing the same
US20030072814A1 (en) Topical pharmaceutical composition for the treatment of warts
EP0524587A1 (en) Therapeutic compositions for intranasal administration which include ketorolac TM
US20040086556A1 (en) Transdermal and topical administration of local anesthetic agents using basic enhancers
CN1195524A (en) Pharmaceutical formulation
EP0410099A1 (en) Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
WO2007133944A2 (en) Topical administration of acyclovir
WO1994005258A1 (en) An antivirally active pharmaceutical oil-in-water emulsion containing 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir) or a salt or ester thereof
Sciarra et al. In vitro release of therapeutically active ingredients from polymer matrixes
JPH0676327B2 (en) Steroid ointment formulation
WO1986000806A1 (en) Transdermal delivery of azatadine
Poochikian et al. Heroin: stability and formulation approaches
EP0477289A1 (en) Anhydrous oil-based liquid suspension for delivering a medicament
CA1207238A (en) Use of haloprogin in the treatment of herpes labialis
HU200689B (en) Process for producing endermic pharmaceutical compositions comprising pyrazolo(1,5-a)pyridine derivatives as active ingredient
Peplow et al. Characteristics of indomethacin and naproxen release from silastic polymeric rods in vitro
JPH0320227A (en) External drug for skin
KR100483227B1 (en) Fushidine acid external spray composition
JPH10139687A (en) Skin preparation for external use
JPS63170317A (en) Percutaneously absorbable pharmaceutical of nifedipine for external use
JPH0640920A (en) Treating agent for viral infections

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: GRACEWAY PHARMACEUTICALS, LLC, TENNESSEE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:3M INNOVATIVE PROPERTIES COMPANY;REEL/FRAME:018866/0444

Effective date: 20061229

AS Assignment

Owner name: BANK OF AMERICA, N.A., AS FIRST LIEN COLLATERAL AG

Free format text: FIRST LIEN GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS AND TRADEMARKS;ASSIGNORS:GRACEWAY PHARMACEUTICALS, LLC;CHESTER VALLEY PHARMACEUTICALS, LLC;REEL/FRAME:019035/0859

Effective date: 20061229

AS Assignment

Owner name: BANK OF AMERICA, N.A., AS SECOND LIEN COLLATERAL A

Free format text: SECOND LIEN GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS AND TRADEMARKS;ASSIGNORS:GRACEWAY PHARMACEUTICALS, LLC;CHESTER VALLEY PHARMACEUTICALS, LLC;REEL/FRAME:019055/0032

Effective date: 20061229

AS Assignment

Owner name: CHESTER VALLEY PHARMACEUTICALS, LLC, PENNSYLVANIA

Free format text: RELEASE OF FIRST LIEN SECURITY AGREEMENT IN PATENTS;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:019265/0696

Effective date: 20070503

Owner name: CHESTER VALLEY PHARMACEUTICALS, LLC, PENNSYLVANIA

Free format text: RELEASE OF SECOND LIEN SECURITY AGREEMENT IN PATENTS;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:019265/0704

Effective date: 20070503

Owner name: BANK OF AMERICA, N.A., AS FIRST LIEN COLLATERAL AG

Free format text: FIRST LIEN GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS AND TRADEMARKS;ASSIGNORS:GRACEWAY PHARMACEUTICALS, LLC;CHESTER VALLEY PHARMACEUTICALS, LLC;REEL/FRAME:019265/0712

Effective date: 20070503

Owner name: GRACEWAY PHARMACEUTICALS, LLC, TENNESSEE

Free format text: RELEASE OF FIRST LIEN SECURITY AGREEMENT IN PATENTS;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:019265/0696

Effective date: 20070503

Owner name: GRACEWAY PHARMACEUTICALS, LLC, TENNESSEE

Free format text: RELEASE OF SECOND LIEN SECURITY AGREEMENT IN PATENTS;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:019265/0704

Effective date: 20070503

AS Assignment

Owner name: DEUTSCHE BANK TRUST COMPANY AMERICAS, AS SECOND LI

Free format text: SECOND LIEN GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS AND TRADEMARKS;ASSIGNORS:GRACEWAY PHARMACEUTICALS, LLC;CHESTER VALLEY PHARMACEUTICALS, LLC;REEL/FRAME:019280/0054

Effective date: 20070503

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: MEDICIS PHARMACEUTICAL CORPORATION, ARIZONA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GRACEWAY PHARMACEUTICALS, LLC;REEL/FRAME:027370/0813

Effective date: 20111202

AS Assignment

Owner name: GOLDMAN SACHS LENDING PARTNERS LLC, NEW YORK

Free format text: SECURITY AGREEMENT;ASSIGNOR:MEDICIS PHARMACEUTICAL CORPORATION;REEL/FRAME:030281/0433

Effective date: 20130423

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: BARCLAYS BANK PLC, AS SUCCESSOR AGENT, NEW YORK

Free format text: NOTICE OF SUCCESSION OF AGENCY;ASSIGNOR:GOLDMAN SACHS LENDING PARTNERS, LLC;REEL/FRAME:034749/0689

Effective date: 20150108